scispace - formally typeset
B

Bruce D. Cheson

Researcher at Georgetown University

Publications -  412
Citations -  45739

Bruce D. Cheson is an academic researcher from Georgetown University. The author has contributed to research in topics: Rituximab & Chronic lymphocytic leukemia. The author has an hindex of 76, co-authored 401 publications receiving 40733 citations. Previous affiliations of Bruce D. Cheson include The Advisory Board Company & University of Chicago.

Papers
More filters
Journal ArticleDOI

Revised response criteria for malignant lymphoma

TL;DR: New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Journal ArticleDOI

Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

TL;DR: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL), and two meetings were convened among United States and international lymphoma experts to develop a uniform set of criteria for assessing response in clinical trials.
Journal ArticleDOI

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

TL;DR: Recommendations to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma and non-Hodgkin lymphomas and enhance the ability to compare outcomes of clinical trials are made.
Journal ArticleDOI

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

TL;DR: An International Working Group met to revise the diagnostic and response criteria for acute myelogenous leukemia originally published in 1990, as well as to provide definitions of outcomes and reporting standards to improve interpretability of data and comparisons among trials as mentioned in this paper.